OA11451A - Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems. - Google Patents

Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems. Download PDF

Info

Publication number
OA11451A
OA11451A OA1200000224A OA1200000224A OA11451A OA 11451 A OA11451 A OA 11451A OA 1200000224 A OA1200000224 A OA 1200000224A OA 1200000224 A OA1200000224 A OA 1200000224A OA 11451 A OA11451 A OA 11451A
Authority
OA
OAPI
Prior art keywords
formula
group
phenyl
palladium
compound
Prior art date
Application number
OA1200000224A
Other languages
English (en)
Inventor
Megan Elizabeth Hnatow
Timothy Norris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11451A publication Critical patent/OA11451A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
OA1200000224A 1999-08-31 2000-08-18 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems. OA11451A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161099P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
OA11451A true OA11451A (en) 2003-12-08

Family

ID=22539510

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000224A OA11451A (en) 1999-08-31 2000-08-18 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems.

Country Status (33)

Country Link
EP (1) EP1081144A3 (cs)
JP (1) JP2001106686A (cs)
KR (1) KR20010050274A (cs)
CN (1) CN1286251A (cs)
AP (1) AP2000001909A0 (cs)
AR (1) AR022650A1 (cs)
AU (1) AU5370200A (cs)
BG (1) BG104730A (cs)
BR (1) BR0003888A (cs)
CA (1) CA2316748A1 (cs)
CO (1) CO5180623A1 (cs)
CZ (1) CZ20003159A3 (cs)
EA (1) EA200000803A3 (cs)
EE (1) EE200000513A (cs)
GT (1) GT200000144A (cs)
HR (1) HRP20000565A2 (cs)
HU (1) HUP0003437A3 (cs)
ID (1) ID27128A (cs)
IL (1) IL138089A0 (cs)
IS (1) IS5604A (cs)
MA (1) MA26750A1 (cs)
NO (1) NO20004312L (cs)
NZ (1) NZ506633A (cs)
OA (1) OA11451A (cs)
PA (1) PA8499601A1 (cs)
PE (1) PE20010523A1 (cs)
PL (1) PL342280A1 (cs)
SG (1) SG87145A1 (cs)
SK (1) SK12862000A3 (cs)
SV (1) SV2002000160A (cs)
TN (1) TNSN00176A1 (cs)
TR (1) TR200002530A2 (cs)
UY (1) UY26315A1 (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627644A4 (en) * 2003-05-23 2012-01-18 Hisamitsu Pharmaceutical Co PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION WITH AN NON-TEROIDAL INFLAMMATORY MEDICAMENT AND AN INTERLEUKIN 1A PRODUCTION INHIBITOR
EP1834953A1 (en) * 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
CN103980312B (zh) * 2014-05-27 2016-09-07 广州大学 一种n杂环双膦配体及其合成方法
WO2025038927A1 (en) * 2023-08-16 2025-02-20 Raythera, Inc. Modulators of tnf alpha activity and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281577B6 (sk) * 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze

Also Published As

Publication number Publication date
TNSN00176A1 (fr) 2005-11-10
UY26315A1 (es) 2001-04-30
PA8499601A1 (es) 2002-02-21
CO5180623A1 (es) 2002-07-30
SK12862000A3 (sk) 2002-02-05
BG104730A (en) 2001-09-28
EA200000803A2 (ru) 2001-04-23
HUP0003437A2 (hu) 2001-06-28
SG87145A1 (en) 2002-03-19
IS5604A (is) 2001-03-01
MA26750A1 (fr) 2004-12-20
AP2000001909A0 (en) 2000-09-30
JP2001106686A (ja) 2001-04-17
TR200002530A2 (tr) 2001-04-20
BR0003888A (pt) 2001-12-11
HRP20000565A2 (en) 2001-06-30
KR20010050274A (ko) 2001-06-15
ID27128A (id) 2001-03-01
CZ20003159A3 (cs) 2001-12-12
PL342280A1 (en) 2001-03-12
GT200000144A (es) 2002-02-20
AU5370200A (en) 2001-03-08
CA2316748A1 (en) 2001-02-28
HU0003437D0 (en) 2000-08-30
HUP0003437A3 (en) 2002-08-28
NO20004312D0 (no) 2000-08-30
SV2002000160A (es) 2002-01-23
PE20010523A1 (es) 2001-04-28
EE200000513A (et) 2001-04-16
EP1081144A3 (en) 2001-04-11
EA200000803A3 (ru) 2001-06-25
AR022650A1 (es) 2002-09-04
NO20004312L (no) 2001-03-01
IL138089A0 (en) 2001-10-31
NZ506633A (en) 2001-12-21
CN1286251A (zh) 2001-03-07
EP1081144A2 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
KR100889937B1 (ko) 보리코나졸의 제조방법
OA11451A (en) Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems.
KR20020056814A (ko) 이미다클로프리드의 제조방법
US6239285B1 (en) Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
KR20230058020A (ko) 글루포시네이트 제조 방법
JPS63192768A (ja) 芳香族アミン誘導体
AU2012269895A1 (en) Hybrid molecules containing pharmacophores of fluconazole as antifungal agents and their preparation
CN102432636A (zh) 一种三苯基氧磷连接双噁唑啉配体及其制备方法和应用
US6344563B1 (en) Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
US6346624B1 (en) Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
CN106220554B (zh) 一种芳基吡啶及其衍生物的制备方法
US5266701A (en) Process for production of 2-iminothiazolidines and oxazolidines
CN1450056A (zh) 阿立哌唑的制备新方法
KR100311949B1 (ko) 1-[(사이클로펜트-3-엔-1-일)메틸]-5-에틸-6-(3,5-다이메틸벤조일)-2,4-피리미딘다이온의제조방법
AU2017258668A1 (en) Process for the preparation of herbicidal pyridinylimidazolone compounds
Berkessel et al. Synthesis of Novel Tridentate N, O, S and N, N, O Ligands of the Tripod Type in Racemic and Enantiomerically Pure Form
CN116724025A (zh) 唑衍生物的制造方法
EP0381434A1 (en) Process for producing optically active alcohol
JPH0755920B2 (ja) 光学活性アミノアルコールおよびその製造法
JPH05262703A (ja) １−（３，５−ジアルキルフェノキシ）−２−アミノプロパンの製造方法
HK1035364A (en) Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
NZ610143B2 (en) Hybrid molecules containing pharmacophores of fluconazole as antifungal agents and their preparation